A detailed history of Accredited Investors Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Accredited Investors Inc. holds 20,000 shares of VERV stock, worth $128,200. This represents 0.01% of its overall portfolio holdings.

Number of Shares
20,000
Previous 6,397 212.65%
Holding current value
$128,200
Previous $30,000 220.0%
% of portfolio
0.01%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$4.4 - $7.86 $59,853 - $106,919
13,603 Added 212.65%
20,000 $96,000
Q3 2024

Nov 05, 2024

SELL
$4.4 - $7.86 $48,853 - $87,269
-11,103 Reduced 63.45%
6,397 $30,000
Q2 2024

Jul 19, 2024

BUY
$4.76 - $12.79 $11,685 - $31,399
2,455 Added 16.32%
17,500 $85,000
Q1 2024

May 14, 2024

BUY
$10.81 - $17.96 $162,636 - $270,208
15,045 New
15,045 $199,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $384M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Accredited Investors Inc. Portfolio

Follow Accredited Investors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Accredited Investors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Accredited Investors Inc. with notifications on news.